Login to Your Account

Clavis Faces Merger, Shutdown in Wake of Elacytarabine Miss

By Nuala Moran
Staff Writer

Wednesday, April 3, 2013
Clavis Pharma A/S is facing a merger or an orderly shutdown following the Phase III failure of elacytarabine, its lipid-enhanced version of cytarabine, in the 380-patient CLAVELA trial in advanced acute myeloid leukemia (AML).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription